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Introduction
Endpoints are outcome measures used to
address the objectives of a clinical trial.
The primary endpoint is the most
important outcome and is used to assess
the primary objective of a trial (e.g., the
variable used to compare the effect
difference of two treatment groups). A
fundamental principle in the design of
randomized trials involves setting out in
advance the endpoints that will be
assessed in the trial [1], as failure to
prespecify endpoints can introduce bias
into a trial and creates opportunities for
manipulation. However, sometimes new
information may come to light that could
merit changes to endpoints during the
course of a trial. This new information
might include, for example, results from
other trials or identiﬁcation of better
biomarkers or surrogate outcome
measures. Such changes can allow
incorporation of up-to-date knowledge
into the trial design. However, changes to
endpoints can also compromise the
scientiﬁc integrity of a trial. Here I
discuss some of the issues and decision-
making processes that should be
considered when evaluating whether to
make changes to endpoints, and discuss
the documentation and reporting of
clinical trials that have revised endpoints.
Changing Endpoints
Many trials have changed their study
endpoints after trial initiation. For
example, a recent study [2] concluded
that pioglitazone was associated with a
signiﬁcantly longer period in which
patients remained free from death,
myocardial infarction, or stroke, which
was a composite endpoint. Conclusions
from this report were questioned [3]
because it was believed that the
composite endpoint was not prespeciﬁed.
This belief was based upon a previous
publication [4] which listed the trial
endpoints, but did not identify this
speciﬁc composite. Authors of the
original article responded to this
criticism [5], stating that after initiation
of the trial, the study executive committee
recognized that the composite endpoint
was not part of the original statistical
analysis plan and thus the composite was
subsequently added. The trialists also
noted that the composite endpoint was
documented in a revised analysis plan
before unblinding the trial data.
More generally, Chan et al. [6]
compared published articles with
protocols for 102 randomized trials
approved by the Scientiﬁc-Ethical
Committees for Copenhagen and
Frederiksberg, Denmark in 1994–1995,
and reported that 62% of the trials had
at least one primary endpoint that had
been changed, introduced, or omitted.
Chan et al. [7] compared published
articles with protocols for 48 randomized
trials approved for funding by the
Canadian Institutes of Health Research
in 1990–1998, and reported that primary
endpoints differed between protocols and
publications in 40% of the trials. Given
that changes to endpoints are so frequent,
it’s important to evaluate when such
changes are appropriate and how they
should be reported.
Guiding Principles
The principle consideration when
evaluating whether to modify an
endpoint is whether the decision is
independent of the data obtained from
the trial to date. If the decision to revise
endpoints is independent of the data
from the trial, then such revisions may
have merit. In fact, Wittes [8] encourages
consideration of changes in long-term
trials, as medical knowledge evolves or
when assumptions made in design of the
trial appear questionable. Wittes further
argues that researchers ‘‘may consider
changes to the primary endpoint when
the trial has airtight procedures to
guarantee separation of the people
involved in making such changes from
data that could provide insight into
treatment effect’’ [8].
Some trials have successfully changed
endpoints after the trials began by
maintaining independence between the
decision and the trial data. For example,
the randomized Post-CABG (Post
Coronary Artery Bypass Graft) trial [9]
compared two lipid-lowering regimens in
patients who had coronary artery bypass
surgery. The investigators explicitly did
not identify a primary endpoint when
they designed the trial. An angiogram to
assess lipid deposition in the coronary
arteries was conducted at entry and then
again ﬁve years later. The researchers
planned to compare changes in lipid
deposition over the ﬁve-year interval
between the two regimens. Because by
design no endpoint would be available for
ﬁve years after randomizing the ﬁrst
participant, the protocol team used this
period to deﬁne the endpoint and to
develop methods for analyses. Although
the endpoint was not prespeciﬁed in the
design phase, a practice that is not
generally recommended, trial leadership
ensured that the selection of the endpoint
was independent of data from the trial.
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endpoint is not independent of the trial
data, then ‘‘cherry-picking’’ is a serious
concern. New endpoints may be selected
because they displayed a trend towards
signiﬁcance, while other candidate
endpoints may have been examined but
not selected or reported because they
failed to display a desirable trend; this
increases the chance of false positive
(type 1) errors. In the Physicians’ Health
Study [10,11], the trial’s data monitoring
committee (DMC) recommended
termination of the study because interim
data seemed unlikely to show any beneﬁt
of aspirin with respect to the primary
endpoint, total mortality. At the time this
decision was made, there was evidence of
beneﬁt with respect to myocardial
infarction. However, the United States
Food and Drug Administration did not
approve an indication for aspirin for the
prevention of myocardial infarction,
because this was not the prespeciﬁed
primary endpoint.
When Is a Decision Independent of
Data?
To evaluate whether a change in
endpoint is independent of data from
the trial, investigators and reviewers
should ask three important questions.
First, what is the source of the new
information that elicits consideration of
the change in endpoints? If the source is
external to the trial in question, for
example arising from results from
another trial, then the revision of
endpoints may be credible. Second, have
interim data on the endpoint (or related
data) from a trial been reviewed? If trial
data have not been reviewed, then the
revision of endpoints may again be
credible. Third, and most importantly,
who is making the decision regarding
endpoint revision (e.g., trial sponsors or
an independent external advisory
committee)? Appropriate decision
makers should have no knowledge of the
endpoint (or related trial data) results. In
particular, if interim analyses have been
conducted, the decision makers should
not have knowledge of those data. Note,
however, that even if no formal interim
analysis has been conducted, any
impressions that the investigators may
have of the trial to date may inﬂuence
decisions regarding changes in endpoints.
For example, investigators may have a
‘‘sense’’ of the endpoint result or a
related variable even though formal
analysis of the endpoint has not been
conducted. An investigator may notice
changes in certain patients at his or her
site and may attribute these changes to
the investigational medication. This can
be particularly problematic in unblinded
trials. For these reasons, study sponsors,
investigators, and DMCs may not be
appropriate decision makers for
endpoint revisions.
Appropriate Decision Makers
Since the decision to revise endpoints
should be independent of the trial data, a
DMC that has reviewed interim data may
not be appropriate for making decisions
regarding endpoint revisions. Even DMC
review of pooled data can suggest
treatment effects (e.g., in a two-group
comparison study of response rates, a
very high pooled response implies a
relatively high response rate in both
groups). In this case, trial leadership
may wish to convene an external
advisory committee that has not reviewed
data from the trial to assess the potential
impact on the integrity of the trial and to
make recommendations regarding
endpoint revision.
Scientific Relevance
It is also important to consider the
scientiﬁc relevance of the endpoints in
question. Does the current state of
k n o w l e d g em a k et h er e s u l t so ft h e
current trial uninformative or inefﬁcient?
Is the trial now scientiﬁcally uninteresting
or irrelevant? If so, then changing
endpoints may be constructive, and
perhaps even ethically necessary, to
ensure that the study generates a
scientiﬁc contribution. For example, new
scientiﬁc questions may arise after
recently completed trials have already
answered the original question of
interest. Also, better biomarkers or
surrogates may have been identiﬁed, or
there may have been changes in regulatory
oversight.
One should be cautious of potential
operational bias induced by the revision
of endpoints. Operational bias is created
when the conduct of clinical investigators
or participants is changed by knowledge
(or perceived knowledge) of trial data.
Knowledge of revisions to endpoints may
inﬂuence the actions of clinical
investigators or participants as they
anticipate the reasons for such revisions.
For example, if a decision to change the
primary endpoint is made, then
participating clinicians and patients may
believe that such a change was made due
to a lack of efﬁcacy of the intervention.
This belief may affect their willingness to
participate, affecting accrual and
retention.
Documentation and Reporting
If the trial leadership decides to modify
endpoints, then appropriate
documentation is crucial. Changes
should be described in amendments to
the protocol and the analysis plan. The
registry record for the trial should also be
updated.
Changes in endpoints should also be
declared when submitting a manuscript
to a journal, so that the results can be
properly evaluated. Reporting of a
clinical trial with any modiﬁed endpoint
should include: (1) a clear statement
describing the fact that information
obtained after trial initiation led to the
change in endpoint; (2) a description of
the reasons (e.g., whether the endpoint
was suggested by the data) and decision
procedure (e.g., who made the decision
and whether data were unblinded); (3) a
discussion of the potential biases induced
Box 1. Proposal for Handling
Changes in Endpoints in Clinical
Trials
Questions to Ask:
 What is the source of the new information
that triggers consideration of a change in
endpoints?
 Have interim data on the endpoint (or
related data) been reviewed?
 Who is making the decision to change
endpoints? Are trial sponsors involved, or
is there an independent external advisory
committee?
Documenting the Endpoint
Changes:
 Update the protocol in a formal protocol
amendment.
 Update the clinical trial registry record.
 Revise the statistical analysis plan.
Reporting the Trial Results:
 Include a clear statement describing the
changes in endpoints, and the
information obtained after the start of the
trial that led to these changes.
 Include a description of the reasons for
these changes and the decision-making
procedure.
 Consider the potential biases that may
have come about as a result of the change
in endpoints.
 Consider including a disclaimer that the
results should be interpreted with caution
and may need to be confirmed in future
trials.
 Report the reasons for excluding
endpoints from the analyses and whether
this was independent of trial data.
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warranted, (i.e., if the decision to add
endpoints was not independent of the
data), a disclaimer that the results should
be interpreted with caution and should
be conﬁrmed in future trials; and (5) a
report of the reasons for excluding
endpoints from the analyses and
whether this was independent of trial
data. Addressing these items will help
ensure clarity and transparency of the
analyses, enable the evaluation of the
independence of the endpoint revision
and trial data as well as the potential for
selective reporting, allow assessment of
the ramiﬁcations of the endpoint revision,
and help avoid overinterpretation of the
data. Researchers may further consider
focusing on descriptive analyses using
conﬁdence intervals rather than
hypothesis testing to avoid overstating
the signiﬁcance of the results.
Hawkey [12] suggests that journals
require submission of the protocol
alongside manuscripts describing clinical
trial results, to help ensure that the
reported endpoints indeed reﬂect what
was deﬁned at the start of the trial.
Several journals have adopted this
policy, including PLoS Clinical Trials, The
Lancet, and the British Medical Journal.
Other journals are considering a
requirement to submit raw data (see the
Harvard School of Public Health’s
Workshop on Assuring the Integrity of
Reporting and Patient Safety in
Therapeutic Trials; http://www.biostat.
harvard.edu/events/schering-plough/
agenda.html). Notably, for industry-
sponsored studies, the Journal of the
American Medical Association is requiring
that analyses be conducted by an
independent statistician at an academic
institution, in part to protect against post
hoc endpoint revisions.
Precise Definitions
Often, prespeciﬁed endpoints are deﬁned
vaguely or ambiguously. For example, a
protocol designed to study the effects of
24 weeks of a new investigational drug on
immune function might specify ‘‘CD4
count’’ as an endpoint. This endpoint
could be interpreted in many different
ways, including, for example: (1) CD4
c o u n ta tw e e k2 4 ;( 2 )c h a n g e sf r o m
baseline in CD4 count at week 24; (3)
the occurrence of a doubling of CD4
count from baseline; or (4) the
occurrence of at least a 50-cell increase
in CD4 count from baseline. If a precise
deﬁnition and analysis for each endpoint
are not speciﬁed in advance, it is possible
for many different versions of the
endpoint to be examined, followed by
selection and reporting of the most
desirable result. This form of ‘‘cherry-
picking’’ inﬂates the false positive error
rate and leads to an underreporting of
negative evidence. Thus it is critical to
prespecify the precise deﬁnition of the
primary endpoint together with the
method of statistical analysis that will be
applied [1].
An Alternative for Large Trials
In certain cases, it may be appropriate to
change or identify endpoints after
initiation of a trial, even when the
decision is based on data from the trial.
For example, if a trial is very large and of
long duration, then investigators may
divide the trial into two stages: a
hypothesis-generating stage in which
endpoints are identiﬁed, and a
subsequent hypothesis-testing stage. In
this case, statistical testing would be
based only on data collected after the
ﬁrst stage was complete.
Conclusions
Revisions to endpoints (particularly
primary endpoints) should be uncommon.
If not appropriately evaluated, such
revisions lead to misguided research and
suboptimal patient care. If, however,
important scientiﬁc knowledge has been
gained after a trial begins, then this
knowledge should be carefully and
responsibly evaluated for incorporation
into the trial. We should be open-minded
and ﬂexible in situations that may
warrant the revision of endpoints and
apply appropriate decision-making and
reporting procedures when such
situations arise. “
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